Forte Biosciences Inc (FBRX)

$32.49 +2.83 (9.54%)
Market Cap 371.55M
Revenue (ttm) 0.00
Net Income (ttm) -35.48M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 334,600
Avg Vol 150,996
Day's Range N/A - N/A
Shares Out 12.53M
Stochastic %K 90%
Beta 3.22
Analysts Strong Sell
Price Target $63.75

Company Profile

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Industry: Biotechnology
Sector: Healthcare
Phone: 310 618 6994
Address:
3060 Pegasus Park Drive, Building 6, Dallas, United States
G_D_1
G_D_1 Jan. 13 at 3:17 PM
$FBRX Delaware court rules in D&O dispute by Gavin Souter Jan 12, 2026 In Forte Biosciences Inc. v. Wesco Insurance Co., Beazley Insurance Co. Inc., and Palms Insurance Co. Ltd., the Delaware Superior Court ruled that coverage fell under policies issued by AmTrust unit Wesco and Cayman Islands-based captive Palms, rather than the Beazley policy. The suit was dismissed after Forte and Camac agreed to various changes, and Forte sought coverage for related expenses from its D&O insurers. The three insurers sought rulings that their policies did not cover Forte. There is a meaningful link “between the 2022 demand which Wesco accepted as a notice of circumstances and the 2023 lawsuit because they allege the same underlying conduct,” the court said, ruling that the Wesco and Palms policies applied. Wesco did not respond to a request for comment.
0 · Reply
Godwins26
Godwins26 Jan. 12 at 6:53 PM
Watchlist $PASW $KC $FBRX $DAWN $SOGP
0 · Reply
topstockalerts
topstockalerts Jan. 12 at 5:53 PM
$FBRX Setting up nicely for continuation. Price is consolidating near highs. That often leads to another push 🚀.
0 · Reply
G_D_1
G_D_1 Jan. 12 at 5:35 PM
$FBRX any news ?
0 · Reply
Paru111
Paru111 Jan. 12 at 5:25 PM
$FBRX huge upside potential
0 · Reply
topstockalerts
topstockalerts Jan. 12 at 5:17 PM
$FBRX Is it going higher?? Comment below
0 · Reply
topstockalerts
topstockalerts Jan. 12 at 4:48 PM
$FBRX This one was on watch and now it’s moving 👀. Buyers stepped in right on time. That’s how breakouts start.
0 · Reply
topstockalerts
topstockalerts Jan. 12 at 4:18 PM
Top Gainers PT2 $BEAM $CLRB $SOGP $FBRX $CRWG
0 · Reply
porky1963
porky1963 Jan. 12 at 3:59 PM
$FBRX told you the last few months it will run.
1 · Reply
topstockalerts
topstockalerts Jan. 12 at 3:51 PM
$FBRX Momentum plays are lighting up again 🔥. Buyers are chasing strength. This environment rewards trend followers.
0 · Reply
Latest News on FBRX
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules

Dec 22, 2025, 4:01 PM EST - 22 days ago

Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules

Forte Biosciences, Inc. Announces Third Quarter 2025 Results and Provides Update

Nov 14, 2025, 9:00 AM EST - 2 months ago

Forte Biosciences, Inc. Announces Third Quarter 2025 Results and Provides Update

Forte Biosciences, Inc. to Present at Upcoming Healthcare Conferences

Nov 3, 2025, 4:01 PM EST - 2 months ago

Forte Biosciences, Inc. to Present at Upcoming Healthcare Conferences

Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules

Oct 3, 2025, 4:01 PM EDT - 3 months ago

Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules

Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium

Sep 15, 2025, 9:00 AM EDT - 4 months ago

Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium

Forte Biosciences, Inc. Announces Results and Provides Update

Aug 14, 2025, 4:01 PM EDT - 5 months ago

Forte Biosciences, Inc. Announces Results and Provides Update

Forte Biosciences Announces Pricing of $75 Million Public Offering

Jun 25, 2025, 12:28 AM EDT - 7 months ago

Forte Biosciences Announces Pricing of $75 Million Public Offering

Forte Biosciences Announces Proposed Public Offering

Jun 24, 2025, 4:01 PM EDT - 7 months ago

Forte Biosciences Announces Proposed Public Offering

Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study

Jun 23, 2025, 7:18 AM EDT - 7 months ago

Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study

Forte Biosciences, Inc. Announces Results and Provides Clinical Update

Mar 31, 2025, 9:00 AM EDT - 10 months ago

Forte Biosciences, Inc. Announces Results and Provides Clinical Update

Forte Biosciences, Inc. to Present at Upcoming Investor Meetings

Feb 3, 2025, 9:00 AM EST - 1 year ago

Forte Biosciences, Inc. to Present at Upcoming Investor Meetings

Forte Biosciences to Host R&D Day December 3, 2024

Nov 25, 2024, 9:00 AM EST - 1 year ago

Forte Biosciences to Host R&D Day December 3, 2024

Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications

Nov 20, 2024, 9:00 AM EST - 1 year ago

Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications

Forte Biosciences, Inc. Announces Third Quarter 2024 Results and Provides Business Update

Nov 14, 2024, 4:01 PM EST - 1 year ago

Forte Biosciences, Inc. Announces Third Quarter 2024 Results and Provides Business Update

Forte Biosciences, Inc. Announces Second Quarter 2024 Results and Provides Business Update

Aug 14, 2024, 4:01 PM EDT - 1 year ago

Forte Biosciences, Inc. Announces Second Quarter 2024 Results and Provides Business Update

Forte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business Update

May 13, 2024, 4:05 PM EDT - 1 year ago

Forte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business Update

Forte Biosciences, Inc. Announces 2023 Results and Provides Business Update

Mar 18, 2024, 4:05 PM EDT - 1 year ago

Forte Biosciences, Inc. Announces 2023 Results and Provides Business Update

Forte Biosciences, Inc. Announces Third Quarter 2023 Results and Provides Business Update

Nov 13, 2023, 4:01 PM EST - 2 years ago

Forte Biosciences, Inc. Announces Third Quarter 2023 Results and Provides Business Update

ISS and Glass Lewis Recommend Forte Biosciences Stockholders Vote FOR Boardroom Change at the Company's Upcoming Annual Meeting

Sep 14, 2023, 10:50 AM EDT - 2 years ago

ISS and Glass Lewis Recommend Forte Biosciences Stockholders Vote FOR Boardroom Change at the Company's Upcoming Annual Meeting

Concerned Stockholders of Forte Biosciences and Its Independent Director Candidates Share Key Facts that Reinforce the Need for Urgent Change in the Company's Boardroom

Sep 6, 2023, 3:15 PM EDT - 2 years ago

Concerned Stockholders of Forte Biosciences and Its Independent Director Candidates Share Key Facts that Reinforce the Need for Urgent Change in the Company's Boardroom

Concerned Stockholders of Forte Biosciences File Definitive Proxy Statement and Send Letter to Stockholders

Aug 25, 2023, 8:00 AM EDT - 2 years ago

Concerned Stockholders of Forte Biosciences File Definitive Proxy Statement and Send Letter to Stockholders

Forte Biosciences, Inc. Announces Second Quarter 2023 Results and Provides Business Update

Aug 14, 2023, 4:01 PM EDT - 2 years ago

Forte Biosciences, Inc. Announces Second Quarter 2023 Results and Provides Business Update

Forte Biosciences, Inc. Announces $25 Million Financing and R&D Update for FB-102

Aug 1, 2023, 4:01 PM EDT - 2 years ago

Forte Biosciences, Inc. Announces $25 Million Financing and R&D Update for FB-102

Forte Biosciences, Inc. Announces First Quarter 2023 Results and Provides Business Update

May 15, 2023, 4:01 PM EDT - 2 years ago

Forte Biosciences, Inc. Announces First Quarter 2023 Results and Provides Business Update

Forte Biosciences, Inc. Announces Full Year 2022 Results and Provides Business Update

Mar 31, 2023, 4:05 PM EDT - 3 years ago

Forte Biosciences, Inc. Announces Full Year 2022 Results and Provides Business Update

Mr. David Gryska Appointed to Forte Biosciences Board of Directors

Jan 12, 2023, 4:05 PM EST - 3 years ago

Mr. David Gryska Appointed to Forte Biosciences Board of Directors

Dr. Scott Brun, M.D. Appointed to Forte Biosciences Board of Directors

Nov 14, 2022, 4:01 PM EST - 3 years ago

Dr. Scott Brun, M.D. Appointed to Forte Biosciences Board of Directors

Forte Biosciences, Inc. Announces Third Quarter 2022 Results and Provides Business Update

Nov 14, 2022, 4:01 PM EST - 3 years ago

Forte Biosciences, Inc. Announces Third Quarter 2022 Results and Provides Business Update

Camac Partners Condemns Forte Biosciences' Seemingly Defensive and Unjustifiable Capital Raise

Aug 17, 2022, 8:00 AM EDT - 3 years ago

Camac Partners Condemns Forte Biosciences' Seemingly Defensive and Unjustifiable Capital Raise

Forte Biosciences, Inc. Announces Second Quarter 2022 Results and Provides Business Update

Aug 15, 2022, 4:05 PM EDT - 3 years ago

Forte Biosciences, Inc. Announces Second Quarter 2022 Results and Provides Business Update

Forte Biosciences, Inc. Announces the Appointment of Dr. Hubert Chen, MD as Chief Scientific Officer and President

Jun 7, 2022, 9:00 AM EDT - 3 years ago

Forte Biosciences, Inc. Announces the Appointment of Dr. Hubert Chen, MD as Chief Scientific Officer and President

Forte Biosciences, Inc. Announces First Quarter 2022 Results and Provides Business Update

May 16, 2022, 9:00 AM EDT - 3 years ago

Forte Biosciences, Inc. Announces First Quarter 2022 Results and Provides Business Update

INVESTIGATION REMINDER: The Schall Law Firm Announces It Is Investigating Claims Against Forte Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm

Sep 6, 2021, 12:42 PM EDT - 4 years ago

INVESTIGATION REMINDER: The Schall Law Firm Announces It Is Investigating Claims Against Forte Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm

Why Forte Biosciences Stock Is Down Over 80% Today

Sep 3, 2021, 2:31 PM EDT - 4 years ago

Why Forte Biosciences Stock Is Down Over 80% Today

A small biotech firm just plummeted 82% after abandoning a drug candidate due to failed phase 2 trial

Sep 3, 2021, 12:19 PM EDT - 4 years ago

A small biotech firm just plummeted 82% after abandoning a drug candidate due to failed phase 2 trial

Forte Biosciences stock plunges more than 80% after 'disappointing' trial results of atopic dermatitis treatment

Sep 3, 2021, 7:21 AM EDT - 4 years ago

Forte Biosciences stock plunges more than 80% after 'disappointing' trial results of atopic dermatitis treatment

Forte Biosciences Just Plummeted 80%: Here's Why

Sep 2, 2021, 5:47 PM EDT - 4 years ago

Forte Biosciences Just Plummeted 80%: Here's Why

Clinical Trial of FB-401 For the Treatment of Atopic Dermatitis Fails to Meet Statistical Significance

Sep 2, 2021, 4:05 PM EDT - 4 years ago

Clinical Trial of FB-401 For the Treatment of Atopic Dermatitis Fails to Meet Statistical Significance

Forte Biosciences, Inc. to Review the Second Quarter 2021 Results and Expects to Announce Topline Data From Phase 2 Clinical Trial of FB-401 for the Treatment of Atopic Dermatitis on Sept. 7

Aug 16, 2021, 4:05 PM EDT - 4 years ago

Forte Biosciences, Inc. to Review the Second Quarter 2021 Results and Expects to Announce Topline Data From Phase 2 Clinical Trial of FB-401 for the Treatment of Atopic Dermatitis on Sept. 7

Forte Biosciences, Inc. (FBRX) CEO Paul Wagner on Q1 2021 Results - Earnings Call Transcript

May 11, 2021, 7:24 AM EDT - 5 years ago

Forte Biosciences, Inc. (FBRX) CEO Paul Wagner on Q1 2021 Results - Earnings Call Transcript

Forte Biosciences, Inc. Announces First Quarter 2021 Results and Provides a General Business Update

May 10, 2021, 4:05 PM EDT - 5 years ago

Forte Biosciences, Inc. Announces First Quarter 2021 Results and Provides a General Business Update

Forte Biosciences, Inc. to Announce First Quarter 2021 Results and Provide a General Business Update

May 3, 2021, 4:30 PM EDT - 5 years ago

Forte Biosciences, Inc. to Announce First Quarter 2021 Results and Provide a General Business Update

Forte Biosciences: Microbiome Therapeutics For Skin Disease

Apr 9, 2021, 6:07 AM EDT - 5 years ago

Forte Biosciences: Microbiome Therapeutics For Skin Disease

Forte Biosciences: FB-401 Could Become The First Line Topical Therapy In Atopic Dermatitis Market

Apr 8, 2021, 6:59 PM EDT - 5 years ago

Forte Biosciences: FB-401 Could Become The First Line Topical Therapy In Atopic Dermatitis Market

Week 13 MDA Breakout Stocks - April 2021: Short-Term Picks To Give You An Edge

Mar 29, 2021, 12:10 PM EDT - 5 years ago

Week 13 MDA Breakout Stocks - April 2021: Short-Term Picks To Give You An Edge

AMGN AXP CAT IMOM JPM UNH VRA

Forte Biosciences, Inc. Announces 4Q and Full Year 2020 Results and Provides a General Business Update

Mar 24, 2021, 8:00 AM EDT - 5 years ago

Forte Biosciences, Inc. Announces 4Q and Full Year 2020 Results and Provides a General Business Update

Forte Biosciences, Inc. to Announce 4Q and Full Year 2020 Results and Provide a General Business Update

Mar 17, 2021, 4:05 PM EDT - 5 years ago

Forte Biosciences, Inc. to Announce 4Q and Full Year 2020 Results and Provide a General Business Update

Forte Biosciences, Inc. to Present at the Chardan Annual Microbiome Medicines Summit on March 8th

Feb 23, 2021, 4:01 PM EST - 5 years ago

Forte Biosciences, Inc. to Present at the Chardan Annual Microbiome Medicines Summit on March 8th

G_D_1
G_D_1 Jan. 13 at 3:17 PM
$FBRX Delaware court rules in D&O dispute by Gavin Souter Jan 12, 2026 In Forte Biosciences Inc. v. Wesco Insurance Co., Beazley Insurance Co. Inc., and Palms Insurance Co. Ltd., the Delaware Superior Court ruled that coverage fell under policies issued by AmTrust unit Wesco and Cayman Islands-based captive Palms, rather than the Beazley policy. The suit was dismissed after Forte and Camac agreed to various changes, and Forte sought coverage for related expenses from its D&O insurers. The three insurers sought rulings that their policies did not cover Forte. There is a meaningful link “between the 2022 demand which Wesco accepted as a notice of circumstances and the 2023 lawsuit because they allege the same underlying conduct,” the court said, ruling that the Wesco and Palms policies applied. Wesco did not respond to a request for comment.
0 · Reply
Godwins26
Godwins26 Jan. 12 at 6:53 PM
Watchlist $PASW $KC $FBRX $DAWN $SOGP
0 · Reply
topstockalerts
topstockalerts Jan. 12 at 5:53 PM
$FBRX Setting up nicely for continuation. Price is consolidating near highs. That often leads to another push 🚀.
0 · Reply
G_D_1
G_D_1 Jan. 12 at 5:35 PM
$FBRX any news ?
0 · Reply
Paru111
Paru111 Jan. 12 at 5:25 PM
$FBRX huge upside potential
0 · Reply
topstockalerts
topstockalerts Jan. 12 at 5:17 PM
$FBRX Is it going higher?? Comment below
0 · Reply
topstockalerts
topstockalerts Jan. 12 at 4:48 PM
$FBRX This one was on watch and now it’s moving 👀. Buyers stepped in right on time. That’s how breakouts start.
0 · Reply
topstockalerts
topstockalerts Jan. 12 at 4:18 PM
Top Gainers PT2 $BEAM $CLRB $SOGP $FBRX $CRWG
0 · Reply
porky1963
porky1963 Jan. 12 at 3:59 PM
$FBRX told you the last few months it will run.
1 · Reply
topstockalerts
topstockalerts Jan. 12 at 3:51 PM
$FBRX Momentum plays are lighting up again 🔥. Buyers are chasing strength. This environment rewards trend followers.
0 · Reply
Stock_Catcher
Stock_Catcher Jan. 12 at 2:59 PM
$FBRX daily chart
0 · Reply
BuyhighseIIIow
BuyhighseIIIow Jan. 12 at 2:53 PM
$FBRX anyone know whats going on?
0 · Reply
JackDarwin
JackDarwin Jan. 8 at 12:11 PM
$FBRX Three Inside Up Candlestick Pattern Formed
0 · Reply
porky1963
porky1963 Jan. 7 at 8:20 PM
$FBRX its on the up
0 · Reply
Paru111
Paru111 Jan. 7 at 4:25 PM
$FBRX $50 coming soon
0 · Reply
porky1963
porky1963 Jan. 4 at 11:24 AM
$FBRX $24.45 MULTIPLY 41741 units held by chief insider = $10 MILLION or am i wrong and need to go back to school.
0 · Reply
porky1963
porky1963 Jan. 4 at 10:01 AM
$FBRX bit of a dive but expected over holidays .banking on big climbs over next few months.glad i got more wen %15 drop.can see it easily beating its $31 high.what you all think ?.
0 · Reply
G_D_1
G_D_1 Jan. 3 at 8:22 AM
$FBRX Insider Buying: Antony Riley Acquires Shares of Forte Biosciences Inc (FBRX) On December 30, 2025, Antony Riley, Chief Financial Officer of Forte Biosciences Inc, purchased 9,680 shares of the company. Following this transaction, the insider now holds a total of 41,741 shares. The transaction details are available in the SEC Filing. Forte Biosciences Inc (FBRX, Financial) is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory skin diseases. The company's lead product candidate is FB-401, which is being developed for the treatment of atopic dermatitis. The insider transaction history for Forte Biosciences Inc indicates that there has been one insider buy in total over the past year, with no insider sells during the same period. This recent purchase by Antony Riley represents the only insider buy in the past year.
1 · Reply
porky1963
porky1963 Dec. 28 at 11:38 AM
$FBRX wonder if this will hit $33-$37 this time in a month,what you think.
0 · Reply
G_D_1
G_D_1 Dec. 26 at 10:25 AM
$FBRX 🤪
0 · Reply
LinkLord
LinkLord Dec. 26 at 8:35 AM
$FBRX The thesis is evolving from vision-led to process-driven as scrutiny intensifies. Competitive positioning has to show up clearly in reported metrics. Operational wins could gradually shift expectations upward. Investors will demand validation before expanding exposure.
0 · Reply
G_D_1
G_D_1 Dec. 22 at 4:29 PM
$FBRX $31
0 · Reply